biotech news today obesity drugs glp-1 Agonists Market Report 2025-2033, By Product, Molecule, and Geo CVS obesity drug deal puts

In conclusion, GLP-1 agonists are a promising treatment option for weight loss in PCOS patients

GLP-1 degradation Native GLP-1 has a very short half-life, which, depending on the species, is around 12 min [[182], [183], [184]] and results from two causes: (a) the action of the enzyme dipeptidylpeptidase-4 (DPP-4) and (b) renal elimination

"Our greatest concern is equitable access

Obesity Treatment is Being Explored Through the Development of Oral Medications that Function as GLP- 1 Receptor Agonists Semaglutide A randomized, double-blind, phase III study found that giving adults overweight or obese (without T2DM) 50 mg of oral semaglutide once daily for 68 weeks, in addition to diet and exercise, significantly reduced their body weight in comparison with a placebo (15% vs

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July